Dino's Bar & Grill Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Dino's Bar & Grill

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Clark Kent	2/16/2021 8:54:03 AM
	of 202926

LXX.c LEXX.Q Lexaria promotes DehydraTech Low , low float since the 1 for 30 reverse. Approx 5 million. My only Pharma stock 2021-02-16 07:58 ET - News Release Lexaria Bioscience Corp.'s drug delivery technology, DehydraTech, improves the bioavailability of pharmaceutical ingredients. "Bioavailability is the rate and extent to which a therapeutically active substance enters systemic circulation and becomes available at the required site of action," states the U.S. National Library of Medicine. Intravenous needles are the holy grail of bioavailability - delivering 100% efficiency - which is why hospital patients are typically on an I.V. drip. Orally ingested drugs "must pass through the intestinal wall and then the portal circulation to the liver," explains Merck Manual, "both are common sites of First-Pass Metabolism". During The First Pass Effect drugs are metabolized in the liver - resulting in a lower concentration of active drugs in the blood system. A technology that can reduce The First Pass Effect for many drugs will achieve two significant outcomes: 1. increased medical benefits to patients and 2. higher profits to pharmaceutical companies.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next